A detailed history of Private Advisor Group, LLC transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Private Advisor Group, LLC holds 22,500 shares of ANTX stock, worth $29,025. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,500
Previous 22,500 -0.0%
Holding current value
$29,025
Previous $48,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 30, 2024

BUY
$2.78 - $21.53 $62,549 - $484,425
22,500 New
22,500 $73,000
Q2 2023

Aug 09, 2023

BUY
$5.06 - $9.91 $230,189 - $450,825
45,492 Added 206.71%
67,500 $573,000
Q1 2023

May 10, 2023

BUY
$7.94 - $15.6 $87,340 - $171,600
11,000 Added 99.93%
22,008 $217,000
Q4 2022

Jan 18, 2023

BUY
$8.51 - $19.69 $93,678 - $216,747
11,008 New
11,008 $0
Q2 2022

Jul 13, 2022

BUY
$7.7 - $18.82 $84,707 - $207,038
11,001 New
11,001 $165,000

Others Institutions Holding ANTX

About AN2 Therapeutics, Inc.


  • Ticker ANTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 19,402,700
  • Market Cap $25M
  • Description
  • AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...
More about ANTX
Track This Portfolio

Track Private Advisor Group, LLC Portfolio

Follow Private Advisor Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Private Advisor Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Private Advisor Group, LLC with notifications on news.